Response to multiple glucose-lowering agents in a sib-pair with a novel HNF1α (MODY3) variant

  • 14 Accesses

Abstract

Maturity-onset diabetes of the young (MODY) is a genetically and clinically heterogeneous group of disorders characterised by early onset, lean, non-autoimmunity mediated, non-insulin-dependent diabetes often with autosomal-dominant inheritance and specific pharmaco-genetic response. We describe two siblings with HNF1A-MODY (MODY3) due to a novel germline variant p.(His126Asp) which segregates with diabetes in the family. However, contrary to anticipated therapeutic response, blood glucose in this sib-pair did not respond to sulphonylureas (both low and high dose), dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), and glucagon-like peptide-1 receptor agonists (GLP-1RA), also known as incretin mimetics. The unexpected limited pharmaco-therapeutic response could potentially be unique to this specific variant and/or progressive pancreatic β-cell failure associated with long-standing disease duration, higher BMI and glucose-toxicity. Therefore, we report a novel-variant MODY3 sib-pair with atypical pharmaco-therapeutic response i.e. resistant to multiple anti-diabetes agents namely sulphonylurea, DPP-4 inhibitors and GLP-1RA treatment.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Jason F, Stefan J, Pal RN. Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes. Nat Rev Endo 2016;12:394–406.

  2. 2.

    Molven A, Njolstad PR. Role of molecular genetics in transforming diagnosis of diabetes mellitus. Expert Rev Mol Diagn. 2011;11:313–20.

  3. 3.

    Shields BM, Hicks S, Shephard MH, Colclough K, Hattersley AT, Ellard S, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53:2504–8.

  4. 4.

    Owen KR, Thanabalasingham G, James TJ, Karpe F, Farmer AJ, McCarthy MI, et al. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care. 2010;33:1919–24.

  5. 5.

    Østoft SH. Incretin hormones and maturity onset diabetes of the young-pathophysiological implications and anti-diabetic treatment potential. Dan Med J. 2015;62:B4860.

  6. 6.

    Østoff SH, Bagger JI, Hansen T, Pedersen O, Holst JJ, Knop FK, et al. Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young-type 2 and type 3. Diabetes. 2014;63:2838–44.

  7. 7.

    Juszczak A, Owen KR. Identifying subtypes of monogenic diabetes. Diabetes Manag. 2014;4:49–61.

  8. 8.

    Demol S, Lebenthal Y, Bar-Meisels M, Phillip M, Gat-Yablonski G, Gozlan Y. A family with a novel termination mutation in hepatic nuclear factor 1α in maturity-onset diabetes of the young type 3 which is unresponsive to sulphonylurea therapy. Horm Res Paediatr. 2014;81:280–4.

  9. 9.

    Harries LW, Hattersley AT, Ellard S, Messenger RNA. Transcripts of the hepatocyte nuclear factor-1alpha gene containing premature termination codons are subject to nonsense-mediated decay. Diabetes. 2004;53:500–4.

  10. 10.

    Steele AM, Shields BM, Shepherd M, Ellard S, Hattersley AT, Pearson ER, et al. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med. 2010;27:157–61.

  11. 11.

    Lachanse CH. Practical aspects of monogenic diabetes: a clinical point of view. Can J Diabetes. 2016;40:368–75.

  12. 12.

    Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362:1275–81.

  13. 13.

    Martagon AJ, Bello-Chavolla OY, Arellano-Campos O, Alemda-Valdes P, Walford GA, Cruz-Bautista I, et al. Mexican carriers of the HNF1A p.E508K variant do not experience an enhanced response to sulphonylureas. Diabetes Care. 2018;41:1726–31.

  14. 14.

    Shephard MH, Shields BM, Hudson M, Pearson ER, Hyde C, Ellard S, et al. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. Diabetologia. 2018;61:2520–7.

  15. 15.

    Wobser H, Bonner C, Nolan JJ, Byrne MM, Prehn JH. Downregulation of protein kinase B/Akt-1 mediates INS-1 insulinoma cell apoptosis induced by dominant negative suppression of hepatocyte nuclear factor-1alpha function. Diabetologia. 2006;49:519–26.

Download references

Acknowledgements

We would like to thank the patients for giving their consent to take part in our study and members of the KTPH Diabetes Centre for their continuing support. The work was supported by NHG-KTPH Small Innovative Grant II/14001 and KTPH STAR17201.

Author information

Correspondence to Su Chi Lim.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tan, C.S.H., Ang, S.F. & Lim, S.C. Response to multiple glucose-lowering agents in a sib-pair with a novel HNF1α (MODY3) variant. Eur J Hum Genet (2019). https://doi.org/10.1038/s41431-019-0561-8

Download citation